Ito Sachiko, Suto Takashi, Saito Shigeru, Obata Hideaki
From the Department of Anesthesiology, Gunma University Graduate School of Medicine, Gunma, Japan.
Center for Pain Management, Department of Anesthesiology, Fukushima Medical University Hospital, Fukushima Medical University, Fukushima, Japan.
Anesth Analg. 2018 Jan;126(1):298-307. doi: 10.1213/ANE.0000000000002380.
Antidepressants are used to treat neuropathic pain and although the detailed mechanisms of their effects are unclear, the descending noradrenergic inhibitory system might play an important role. We tested our hypothesis that repeated administration of duloxetine suppresses neuropathic pain by restoring the descending noradrenergic inhibitory system in rats 6 weeks after spinal nerve ligation (SNL).
We subcutaneously injected SNL rats with duloxetine (10 mg kg day) daily for 3 consecutive days and assessed behavioral hypersensitivity and noxious stimulus-induced analgesia (NSIA) activated by subcutaneous injection of capsaicin. We also performed microdialysis studies of the spinal cord, noradrenaline measurements of homogenized lumbar spinal tissue, and immunohistochemistry of the locus coeruleus.
Three daily injections of duloxetine attenuated the mechanical hyperalgesia induced by SNL (SNL treated with vehicle: 88 ± 9.4 g versus SNL treated with duloxetine: 148 ± 13 g, P < .001; estimated treatment effect of duloxetine [95% confidence interval {CI}], 65 [50.6-79.4]; n = 6/group, on day 4) and recovered the decreased NSIA (vehicle: 154 ± 10 g versus duloxetine: 213 ± 33 g, P < .001; 71.3 [57.4-85.2]; n = 6/group, 30 minutes after injection). The noradrenaline content in the dorsal spinal cord increased bilaterally (SNL treated with vehicle: 946.7 ± 203.6 pg/g versus SNL treated with duloxetine: 1593.5 ± 181.4 pg/g, P < .001; 646.79 pg/g [481.61-811.97] on the ipsilateral side; SNL treated with vehicle: 845.0 ± 164.7 pg/g versus SNL treated with vehicle: 1557.2 ± 237.4 pg/g, P < .001; 712.17 pg/g [449.31-975.02] on the contralateral side). Intrathecal injection (IT) of the α2-adrenoceptor antagonist idazoxan reversed both the antihyperalgesic effect (before IT: 133 ± 5.7 g versus 30 minutes after IT: 85.8 ± 6.5 g, P < .001, -47 [-39.1 to -54.8], n = 6/group, and NSIA; vehicle-IT: 219 ± 7.4 g versus idazoxan-IT: 153 ± 10 g, P < .001; -65.8 g [-25.2 to -77.4] n = 6/group, 30 minutes after forepaw injection of capsaicin). Duloxetine treatment did not alter the noradrenaline release in the spinal cord after capsaicin injection (P = .415), or the fraction of nuclei positive for phosphorylated cyclic adenosine monophosphate response element binding protein in the locus coeruleus (P = 1.00 duloxetine versus vehicle 120 minutes after forepaw injection of vehicle and P = 1.00 duloxetine versus vehicle 120 minutes after forepaw injection of capsaicin).
These findings suggest that 3 daily injections of duloxetine suppressed hyperalgesia and recovered impaired NSIA in rats 6 weeks after nerve injury. Both effects of duloxetine were reversed by IT of an α2-adrenoceptor antagonist. These findings suggest the inhibitory effects of duloxetine against neuropathic pain depend on recovery of the noradrenergic descending inhibitory system, especially in the spinal cord.
抗抑郁药用于治疗神经性疼痛,尽管其作用的详细机制尚不清楚,但下行去甲肾上腺素能抑制系统可能起重要作用。我们检验了我们的假设,即重复给予度洛西汀可通过恢复大鼠脊髓神经结扎(SNL)6周后下行去甲肾上腺素能抑制系统来抑制神经性疼痛。
我们连续3天每天给SNL大鼠皮下注射度洛西汀(10mg/kg/天),并评估行为超敏反应和皮下注射辣椒素激活的伤害性刺激诱导镇痛(NSIA)。我们还进行了脊髓微透析研究、腰段脊髓组织匀浆去甲肾上腺素测量以及蓝斑核免疫组织化学分析。
连续3天注射度洛西汀可减轻SNL诱导的机械性痛觉过敏(用赋形剂处理的SNL:88±9.4g,而用度洛西汀处理的SNL:148±13g,P<.001;度洛西汀的估计治疗效果[95%置信区间{CI}],65[50.6 - 79.4];每组n = 6,在第4天),并恢复降低的NSIA(赋形剂:154±10g,而度洛西汀:213±33g,P<.001;71.3[57.4 - 85.2];每组n = 6,注射后30分钟)。脊髓背侧去甲肾上腺素含量双侧增加(用赋形剂处理的SNL:946.7±203.6pg/g,而用度洛西汀处理的SNL:1593.5±181.4pg/g,P<.001;同侧为646.79pg/g[481.61 - 811.97];用赋形剂处理的SNL:845.0±164.7pg/g,而用度洛西汀处理的SNL:1557.2±237.4pg/g,P<.001;对侧为712.17pg/g[449.31 - 975.02])。鞘内注射(IT)α2 - 肾上腺素能拮抗剂咪唑克生可逆转抗痛觉过敏作用(IT前:133±5.7g,而IT后30分钟:85.8±6.5g,P<.001,-47[-39.1至-54.8],每组n = 6)和NSIA;赋形剂 - IT:219±7.4g,而咪唑克生 - IT:153±10g,P<.001;-65.8g[-25.